Linaclotide

At a glance

---

What is linaclotide?

Linaclotide is a 14-amino-acid synthetic peptide that is structurally related to the body's own guanylin and uroguanylin peptides. Its three intramolecular disulfide bonds make it remarkably stable in the harsh proteolytic environment of the gastrointestinal tract — a property that is essential to how it works.^[7]

It was originally developed by Microbia (later Ironwood Pharmaceuticals) and brought to market in partnership with Forest Laboratories (now part of AbbVie). The FDA approved it in August 2012 under the brand name Linzess for two adult indications: irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). In Europe and Canada it is sold as Constella. In 2023 the FDA approved an expanded label for functional constipation in pediatric patients aged 6 to 17, based on a dedicated pediatric Phase 3 trial.^[5][11]

Why this peptide matters in the broader peptide conversation. Most consumer peptide content focuses on growth hormone analogs, GLP-1 receptor agonists, or research-only compounds like BPC-157 and TB-500. Linaclotide is rarely discussed in that context — yet it is exactly the kind of peptide that deserves attention: a fully FDA-approved 14-mer with a well-defined receptor, robust Phase 3 evidence, more than a decade of post-market safety data, and a clear, unmet medical need.

---

How it works

Linaclotide does two things at once, both starting from the same molecular event.

When you swallow a linaclotide capsule, the peptide travels to the small intestine and binds to guanylate cyclase-C (GC-C) receptors on the luminal (apical) surface of intestinal epithelial cells. GC-C is the same receptor activated by the body's natural guanylin and uroguanylin peptides, and historically by bacterial heat-stable enterotoxins. Activation increases intracellular cyclic GMP (cGMP), which then has two distinct downstream effects.^[7][9]

On the apical (gut lumen) side, cGMP activates the CFTR chloride channel, leading to secretion of chloride and bicarbonate into the intestinal lumen. Water follows by osmosis. The result: softer stool and faster transit through the intestine. This is the laxative mechanism.

On the basolateral (away-from-lumen) side, cGMP is also exported out of the epithelial cell, where it acts on submucosal sensory afferent nerves to reduce their firing in response to colonic distension. The result: reduced visceral pain. This is what differentiates linaclotide from most laxatives — it does not just move things along; it dampens the pain signal that defines IBS-C.^[8]

A critical pharmacological feature: linaclotide has minimal systemic absorption. At therapeutic doses it is essentially undetectable in plasma. This is why its safety profile is so favorable for a chronic-use drug — it almost never leaves the gut.

Detailed mechanism (for advanced readers)

Linaclotide's molecular pharmacology in more detail:

• Primary target: Guanylate cyclase-C (GC-C), a membrane-bound enzyme expressed on the apical surface of intestinal epithelial cells from the duodenum to the rectum
• Endogenous ligands: Guanylin (small intestine) and uroguanylin (more distally). Linaclotide is a synthetic analog of this peptide family, designed for greater stability.
• Stability: Three disulfide bonds (Cys1-Cys6, Cys2-Cys10, Cys5-Cys13) confer resistance to gastric acid and intestinal proteases, allowing oral dosing
• Signaling cascade: GC-C activation generates cyclic GMP from GTP. Intracellular cGMP activates protein kinase G II (PKG II), which phosphorylates and opens the CFTR chloride channel on the apical membrane.
• Fluid secretion: Chloride and bicarbonate efflux into the lumen drives passive water secretion, increasing intraluminal fluid and accelerating transit
• Visceral analgesia: Excess intracellular cGMP is also exported across the basolateral membrane (likely via MRP4/MRP5 transporters) and acts on submucosal sensory nerve endings to suppress mechano-nociception. This pathway, demonstrated in rodent models by Castro and colleagues, explains why linaclotide reduces abdominal pain — not just constipation.^[8]
• Pharmacokinetics: At the 145 mcg and 290 mcg adult doses, linaclotide is essentially undetectable in plasma. The active metabolite (MM-419447) is also gut-restricted. This is the basis of the drug's safety in chronic use.

How it compares to related approaches:

• vs. plecanatide: Plecanatide is also a GC-C agonist, structurally closer to natural uroguanylin and pH-sensitive (more active in the acidic proximal intestine). FDA-approved for CIC and IBS-C. Same mechanism family, different molecule.
• vs. lubiprostone: Lubiprostone activates ClC-2 chloride channels directly. Different target, similar downstream effect (luminal fluid secretion).
• vs. PEG laxatives (osmotic): PEG works as a non-absorbed osmotic agent with no receptor mechanism and no specific effect on visceral pain. Linaclotide adds a pain-modulating mechanism that PEG does not have.
• vs. opioid antagonists (methylnaltrexone, naloxegol, naldemedine): These target peripheral mu-opioid receptors and are specifically for opioid-induced constipation. Different mechanism and different indication.

---

What the research says

Linaclotide has one of the strongest evidence bases of any peptide drug — multiple large Phase 3 RCTs in two adult indications, a confirmatory Phase 3 trial in pediatric patients, long-term safety extensions, and more than a decade of post-market real-world experience. For IBS-C and CIC, the evidence is robust and the regulatory status is unambiguous.

Research timeline

Linaclotide's development is a case study in how a peptide goes from preclinical pharmacology to a multi-indication FDA-approved drug:

Human clinical trials

The linaclotide clinical program is unusually large by peptide standards — multiple pivotal Phase 3 RCTs, long-term safety extensions, and a dedicated pediatric trial:

What stands out, compared to most peptides covered on this site, is that the linaclotide program was designed to FDA pivotal-trial standards from the start. The combined enrollment across the pivotal Phase 3 trials in IBS-C and CIC exceeds 4,000 patients — a level of human evidence that very few peptides ever achieve.

The pain benefit — why linaclotide is different

The single most important thing to understand about linaclotide clinically is that it is not just a laxative.^[6]

Most over-the-counter laxatives (osmotic agents, fiber, stool softeners) increase stool frequency without changing how much pain a patient feels. For IBS-C, where pain and bloating are part of the diagnosis, that is often unsatisfying — patients report that they "go more often" but still feel terrible.

Linaclotide's mechanism dampens visceral pain through a molecular pathway separate from its laxative effect. Castro et al. demonstrated in animal models that cGMP generated by GC-C activation effluxes from intestinal epithelial cells and reduces firing of submucosal sensory neurons.^[8] This is consistent with the clinical Phase 3 data, which shows significant reductions in abdominal pain that can be measured independently of the change in stool frequency.

This pain benefit is the basis of guideline recommendations placing linaclotide as a recommended pharmacological option for IBS-C, distinct from generic laxatives.

The pediatric data

The 2022 pediatric Phase 3 trial (Lacy et al.) enrolled 328 patients aged 6 to 17 with functional constipation. Linaclotide 72 mcg once daily produced a statistically significant increase in spontaneous bowel movement frequency over 12 weeks, with a safety profile consistent with adult data.^[5]

The FDA used this data to approve the pediatric indication in 2023.^[11] Critically, the boxed warning against use in patients under 2 years of age was retained — based on observations of severe dehydration and death in juvenile mice, the youngest age groups were never studied and remain contraindicated.

---

What the evidence shows

People encounter linaclotide through different lenses — IBS-C treatment, chronic constipation, pediatric care, or off-label questions. Here's what the published research actually supports:

---

Safety & side effects

What the Phase 3 and post-market data show

Linaclotide has one of the most thoroughly characterized safety profiles of any peptide drug, documented in its FDA-approved prescribing information and supported by more than a decade of post-market pharmacovigilance:^[10]

Common adverse events (from prescribing information):

• Diarrhea — by far the most common adverse event, affecting roughly 16-20% of patients in pivotal trials. About 5% of patients discontinued treatment because of diarrhea.
• Abdominal pain (often transient, may reflect underlying IBS-C rather than the drug)
• Flatulence
• Abdominal distension
• Headache (less common)

For most patients, diarrhea is dose-related and can often be managed by reducing the dose (e.g., 290 mcg to 145 mcg, or 145 mcg to 72 mcg) or by adjusting timing.

The boxed warning — patients under 2 years

Linaclotide carries a boxed warning against use in patients less than 2 years of age.^[10] In juvenile mice, doses extrapolating to clinical exposures caused severe, sometimes fatal, dehydration. Because infants have less physiological reserve for fluid loss and cannot reliably communicate symptoms, the FDA has restricted use accordingly.

This warning is age-specific, not a general safety concern — for adults, and now for children aged 6 to 17 with functional constipation, the safety profile is well established.

Systemic safety

Because linaclotide is essentially not absorbed into systemic circulation, the kinds of risks seen with systemically active drugs — drug-drug interactions via CYP enzymes, organ toxicity, central nervous system effects — are largely absent. This is one of the most important practical features of the drug for chronic use.

Contraindications and precautions

Contraindications (from prescribing information):

• Patients less than 2 years of age (boxed warning — risk of severe dehydration based on juvenile mouse data)
• Patients with known or suspected mechanical gastrointestinal obstruction

Key precautions:

• Diarrhea — most common adverse event. Severe diarrhea, dehydration, or electrolyte abnormalities should prompt evaluation and possible discontinuation.
• Pediatric patients aged 2 to less than 6: avoid use (extrapolated risk based on juvenile mouse findings; pediatric efficacy and safety established only for ages 6-17).
• Pregnancy: minimal systemic absorption suggests low fetal exposure, but human data are limited; consult prescribing information.
• Patients with active diarrhea or recent significant GI symptoms should be evaluated before starting.

---

How people use it

Unlike most peptides covered on this site, linaclotide is taken orally as a capsule, not by injection — its three disulfide bonds make it stable enough to survive the stomach. There is no reconstitution, no syringe, no compounding-pharmacy workflow. It is a regular pharmacy prescription.

FDA-approved use

The current FDA-approved doses are:^[10]

• Adults with IBS-C: 290 mcg once daily, taken on an empty stomach at least 30 minutes before the first meal of the day
• Adults with CIC: 145 mcg once daily (or 72 mcg if needed), same timing
• Pediatric functional constipation (ages 6-17): 72 mcg once daily, same timing

Taking linaclotide with food (particularly a high-fat meal) can increase the likelihood of looser stools and diarrhea, which is why the on-an-empty-stomach guidance matters.

For pediatric patients who cannot swallow capsules, the prescribing information provides instructions for opening the capsule and administering the contents in applesauce or water — see the current label for the exact procedure.

Off-label and unapproved contexts

Off-label use of linaclotide is uncommon compared to many peptides discussed in consumer contexts — partly because it is a prescription drug with specific approved indications, and partly because its mechanism (gut-restricted GC-C agonism) does not lend itself to the kinds of off-label uses (anti-aging, body composition, performance) that drive most peptide off-label markets.

Some clinicians will discuss linaclotide for adjacent functional GI conditions where chronic constipation is part of the picture, but this is at clinician discretion and not supported by Phase 3 evidence.

What linaclotide is not stacked with

In contrast to many peptides covered on this site, linaclotide does not have a "stacking culture." It is a single-purpose prescription drug with a defined indication, not a compound that gets layered into broader optimization protocols. Combining it with other prescription laxatives or GC-C agonists (e.g., plecanatide) is not standard practice and should be discussed with a prescriber if considered.

---

Legal & regulatory status

As of April 2026:

FDA status

Linaclotide is currently FDA-approved as Linzess for three indications:^[10][11]

1. Irritable bowel syndrome with constipation (IBS-C) in adults — original 2012 approval
2. Chronic idiopathic constipation (CIC) in adults — original 2012 approval
3. Functional constipation in pediatric patients aged 6 to 17 — added 2023

The boxed warning against use in patients under 2 years of age is a key feature of the label.

The NDA holder is AbbVie (after the Allergan acquisition), and the drug is co-commercialized with Ironwood Pharmaceuticals. Linaclotide is a fully approved, branded prescription medication available through normal retail and specialty pharmacies — not a compounded peptide.

WADA / USADA status

Linaclotide is not on the WADA Prohibited List.^[12] It is not classified as a performance-enhancing substance: it acts locally in the gut, has minimal systemic absorption, and has no known doping-relevant effect.

International status

Linaclotide is approved in the European Union, the United Kingdom, Canada, Japan, and many other jurisdictions. It is sold as Constella in the EU and Canada and as Linzess in the US, Japan, and several other markets. Specific indications and dosing may vary by region — check local prescribing information for jurisdiction-specific labels.

---

How linaclotide compares

Linaclotide sits in a small family of FDA-approved prescription treatments for chronic constipation and IBS-C. The closest molecular comparator is plecanatide, another GC-C agonist:

The two GC-C agonists are clinically similar — both improve stool frequency and abdominal symptoms, both are approved for IBS-C and CIC in adults, and both share a similar safety profile dominated by diarrhea. Linaclotide has the longer track record (approved five years earlier), the larger cumulative evidence base, and the pediatric indication. Plecanatide is structurally closer to natural uroguanylin and is pH-sensitive, which some clinicians believe gives a slightly different intestinal distribution. There are no large head-to-head trials to declare a winner; both are reasonable options.

For someone choosing a prescription option for IBS-C or CIC, the choice is typically driven by insurance coverage, prior response to one or the other, and tolerance of diarrhea — not by clear superiority of one molecule over the other.

---

Common exaggerations to watch for

Because linaclotide is a prescription drug with a defined label, the kinds of marketing exaggerations seen with off-label peptides are less common — but a few claims still circulate:

• "Linaclotide cures IBS" — Overstated. Linaclotide significantly improves the symptoms of IBS-C (constipation, abdominal pain, bloating) but it does not cure IBS. Symptoms generally return when treatment is stopped, and effect sizes, while clinically meaningful, leave most patients with some residual symptoms.
• "It works for all forms of IBS" — False. Linaclotide is approved specifically for IBS with constipation (IBS-C). It is not appropriate for IBS with diarrhea (IBS-D) or for the diarrhea-predominant subtype of mixed IBS, and could worsen symptoms in those patients.
• "Linaclotide is just an expensive laxative" — Misleading. Linaclotide does increase stool frequency, but it also reduces visceral pain through a mechanism distinct from osmotic laxatives. This is a clinically meaningful difference for IBS-C patients.
• "Safe for kids of any age because it's not absorbed" — False. The boxed warning specifically contraindicates use in patients under 2 years of age based on juvenile-mouse data showing severe dehydration risk. The pediatric approval is for ages 6 to 17 only.
• "Works for opioid-induced constipation" — Not supported by FDA approval. OIC has dedicated treatments with proven efficacy for that mechanism (methylnaltrexone, naloxegol, naldemedine). Linaclotide is not approved or evidence-supported for OIC.
• "Causes weight loss / supports metabolic health" — Not what it does. Linaclotide is a gut-restricted symptomatic treatment for constipation and IBS-C, not a metabolic drug. Any anecdotal weight changes are likely related to changes in stool frequency, not real metabolic effects.

---

Related content

Peptide

BPC-157 Profile

A different gut-related peptide with very different evidence quality. Compare a research-only compound (BPC-157) with an FDA-approved gut peptide drug (linaclotide).

Peptide

KPV Profile

Another peptide explored for gastrointestinal inflammation, but at a much earlier stage of evidence than linaclotide.

Guide

What Are Peptides?

Linaclotide is a textbook example of a peptide drug: 14 amino acids, FDA-approved, with a clearly characterized receptor target.

News

FDA Peptide Categories Explained

Where linaclotide sits in the regulatory landscape: a fully FDA-approved peptide drug, distinct from compounded or research-only peptides.

---

References

1. [1]

   Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, et al.. “Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.” Am J Gastroenterol. 2012. 107(11):1702-1712 DOI PubMedRCT

   Pivotal Phase 3 RCT for IBS-C. Met all four FDA primary endpoints. Cornerstone of the IBS-C indication.

2. [2]

   Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, et al.. “A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.” Am J Gastroenterol. 2012. 107(11):1714-1724 DOI PubMedRCT

   Companion pivotal Phase 3 RCT. Demonstrated symptom return on withdrawal, supporting causal effect.

3. [3]

   Lembo AJ, Schneier HA, Shiff SJ, Kurtz CB, MacDougall JE, Jia XD, et al.. “Two randomized trials of linaclotide for chronic constipation.” N Engl J Med. 2011. 365(6):527-536 DOI PubMedRCT

   Two pivotal Phase 3 trials in chronic constipation, published together in NEJM. Highest-impact linaclotide publication.

4. [4]

   Chey WD, Lembo AJ, MacDougall JE, Lavins BJ, Schneier HA, Jia XD, et al.. “Long-term safety and efficacy of linaclotide in patients with irritable bowel syndrome with constipation and chronic idiopathic constipation.” Am J Gastroenterol. 2014. 109(11):1702-1714Safety study

   Long-term open-label safety extension. Supports chronic daily use.

5. [5]

   Lacy BE, Schey R, Shiff SJ, Lavins BJ, Fox SM, et al.. “Linaclotide in pediatric patients with functional constipation: a Phase 3 randomized, double-blind, placebo-controlled trial.” J Pediatr Gastroenterol Nutr. 2022.RCT

   Pediatric Phase 3 trial. Basis for the 2023 expanded approval in patients aged 6-17.

6. [6]

   Rao SSC, Quigley EMM, Shiff SJ, Lavins BJ, Kurtz CB, MacDougall JE, et al.. “Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation.” Clin Gastroenterol Hepatol. 2014. 12(4):616-623 DOI PubMedRCT

   Pooled analysis of pivotal Phase 3 IBS-C trials focused on abdominal pain and bloating. Confirms differentiating pain benefit.

7. [7]

   Bryant AP, Busby RW, Bartolini WP, Cordero EA, Hannig G, Kessler MM, et al.. “Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.” Life Sci. 2010. 86(19-20):760-765 DOI PubMedAnimal study

   Foundational preclinical pharmacology paper. Establishes selectivity for GC-C and local gut activity.

8. [8]

   Castro J, Harrington AM, Hughes PA, Martin CM, Ge P, Shea CM, et al.. “Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cGMP.” Gastroenterology. 2013. 145(6):1334-1346 DOI PubMedAnimal study

   Mechanistic paper demonstrating cGMP efflux and reduced nociceptor firing. Explains the differentiating pain benefit observed in clinical trials.

9. [9]

   Busby RW, Bryant AP, Bartolini WP, Cordero EA, Hannig G, Kessler MM, et al.. “Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.” Eur J Pharmacol. 2010. 649(1-3):328-335 DOI PubMedAnimal study

   Demonstrates GC-C-mediated enhancement of intestinal fluid secretion and transit. Mechanism of the laxative effect.

10. [10]

    AbbVie / Ironwood Pharmaceuticals (prescribing information). “LINZESS (linaclotide) capsules — Full Prescribing Information.” 2023. Link

    Current FDA-approved prescribing label. Definitive source for indications, dosing, contraindications (including boxed warning), and adverse event rates.

11. [11]

    U.S. Food and Drug Administration. “FDA approves Linzess (linaclotide) for functional constipation in pediatric patients aged 6 to 17.” 2023. Link

    Regulatory milestone — pediatric label expansion based on Lacy 2022 Phase 3 data.

12. [12]

    World Anti-Doping Agency. “The World Anti-Doping Code International Standard — Prohibited List 2026.” 2026. Link

    Reference for confirming linaclotide is not a prohibited substance.

---